Several epidemiological studies have linked the osteoblast-derived polypeptide osteocalcin (OC) to a reduced incidence of type 2 diabetes and metabolic syndrome (MetS). According to animal research, the undercarboxylated form of OC (ucOC) is responsible for its connection with metabolic outcomes. In this study, researchers looked at the relationships between ucOC and carboxylated OC (cOC) and MetS and its components in older males. A cross-sectional study of 2575 males aged 70 and up living in Perth, Western Australia. The hydroxyapatite-binding technique was used to measure ucOC, and cOC was determined by subtracting ucOC from total OC. MetS and its components were the primary outcome measures. Lower blood ucOC and cOC levels, as well as the percentage of cOC, were linked with less favourable metabolic parameters, whereas percent ucOC was associated with the opposite. Those in the lowest ucOC quintile had a greater risk of MetS than men in the top quintile.

Lower serum ucOC or cOC concentrations were linked to worse metabolic parameters and a greater incidence of MetS. A smaller proportion of ucOC, on the other hand, was related with improved metabolic parameters and a reduced risk of MetS. More study is needed to establish if ucOC and cOC are useful biomarkers for men’s cardiometabolic risk.